[ad_1]
It is this protein, which gives the Corona virus its distinctive coronavirus form, that helps the microorganism adhere to human cells in the early stages of the disease.
Once this foreign protein is produced in the body, the immune system tricks the presence of the virus and begins to produce antibodies, as if the person is already sick.
This method is similar to the way a vaccine works. "Pfizer" Y"Bountech".
Both vaccines require two injections, several weeks apart.
Regarding the vaccine "Modern" A different approach is needed as it consists of small pieces of DNA. "MRNA" That stimulates the body to make the protein found on the surface of the emerging corona virus.
Among the good news is the vaccine. "Modern" It can be stored in conventional refrigerators for a period of 6 months and for a month in refrigerators without losing its effectiveness, unlike other vaccines, which must be stored at extremely cold temperatures of up to minus 70 degrees.
In terms of production and manufacturing, the United States government has allocated $ 2.5 billion to a company "Modern" To support research, testing and the purchase of at least 100 million doses of the vaccine, the company intends to produce 20 million doses this year, all of which will go to the United States.
On the other hand, Pfizer agreed to sell at least 1.1 billion doses of its vaccine to the United States, Europe and Canada, along with Japan and Great Britain, and this is approximately 1.3 billion doses that the company intends to produce by the end of 2021.
Despite this advance in the race to face the epidemic, the risks are still facing the world, in an investigation by the Institute of Global Health at Duke University, revealed that there may not be enough doses to cover the entire population worldwide until 2024.
“>
The frantic race between scientists and pharmaceutical companies to find an antonviral vaccine is paying off, as preliminary results from the vaccine company “Moderna” showed an effectiveness of 94.5% in protecting against the Corona virus that causes the disease. Covid-19, a week after a similar announcement from Pfizer and Biotank on the effectiveness. His vaccination increased by more than 90%.
From a scientific point of view, the two vaccines have a very similar mechanism of action, while the two differ from the predominant patterns followed by the usual vaccines.
It used to be that the vaccine consisted mainly of weak or inactivated viruses or parts of the virus that do not cause disease to the body, but only inform the body of the disease and stimulate it to produce antibodies that remain inside it for life and defend it against this virus in the future.
It is this protein, which gives the Corona virus its distinctive coronavirus form, that helps the microorganism adhere to human cells in the early stages of the disease.
Once this foreign protein is produced in the body, the immune system tricks the presence of the virus and begins to produce antibodies, as if the person is already sick.
This method is similar to how the “Pfizer” and “Biontech” vaccines work.
Both vaccines require two injections, several weeks apart.
As for the “Modern” vaccine, it takes a different approach, as it consists of small pieces of DNA “mRNA” that stimulate the body to produce the protein on the surface of the emerging corona virus.
Among the good news, Moderna vaccine can be stored in regular refrigerators for 6 months and for a month in refrigerators without losing its effectiveness, unlike the other vaccine, which must be stored at extremely cold temperatures of minus 70 degrees.
In terms of production and manufacturing, the United States government has allocated $ 2.5 billion to Moderna to support research, testing, and purchase of at least 100 million doses of the vaccine, while the company intends to produce 20 million. doses this year, all of which will go to the United States.
On the other hand, Pfizer agreed to sell at least 1.1 billion doses of its vaccine to the United States, Europe and Canada, along with Japan and Great Britain, and this is approximately 1.3 billion doses that the company intends to produce by the end of 2021.
Despite this advance in the race to face the epidemic, the risks are still facing the world, in an investigation by the Institute of Global Health at Duke University, revealed that there may not be enough doses to cover the entire population worldwide until 2024.
[ad_2]
